Announced in May 2025, the Dyno Frontiers Program helps gene therapy innovators prove the therapeutic potential of their ...

Company reports Q3 2025 AUCATZYL® net product revenue of $21.1 million and deferred revenue of $7.6 million; 60 authorized treatment centers achieved ahead of targetClinical execution and data ...